

Research article

Quantitative photoacoustic imaging study of tumours in vivo: Baseline variations in quantitative measurements

Márcia Martinho Costa^{a,*}, Anant Shah^{a,1}, Ian Rivens^a, Carol Box^a, Tuathan O'Shea^a,
Efthymia Papaevangelou^b, Jeffrey Bamber^a, Gail ter Haar^a

^a Joint Department of Physics and Cancer Research UK Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust, Sutton, London, SM2 5PT, United Kingdom

^b School of Immunology and Microbial Sciences, Guy's Hospital, King's College London, London, SE1 9RT, United Kingdom

ARTICLE INFO

Keywords:

Photoacoustic imaging
Hypoxia
Head and neck subcutaneous tumours
Pimonidazole
Blood sO₂
Hemoglobin

ABSTRACT

Photoacoustic imaging (PAI) provides information on haemoglobin levels and blood oxygenation (sO₂). To facilitate assessment of the variability in sO₂ and haemoglobin in tumours, for example in response to therapies, the baseline variability of these parameters was evaluated in subcutaneous head and neck tumours in mice, using a PAI system (MSOTinVision-256TF). Tumours of anaesthetized animals (midazolam-fentanyl-medetomidine) were imaged for 75 min, in varying positions, and repeatedly over 6 days. An increasing linear trend for average tumoural haemoglobin and blood sO₂ was observed, when imaging over 75 min. There were no significant differences in these temporal trends, when repositioning tumours. A negative correlation was found between the percent decrease in blood sO₂ over 6 days and tumour growth rate. This paper shows the potential of PAI to provide baseline data for assessing the significance of intra- and inter-tumoural variations that may eventually have value for predicting and/or monitoring cancer treatment response.

1. Introduction

The immature, tortuous and hyperpermeable vascular network often found in tumours may not provide sufficient nutrients and oxygen for rapid and uncontrolled cell proliferation, which can result in regions of tumour cell hypoxia, i.e. low oxygen concentration in the vicinity of tumour cells [1]. Temporal fluctuations in the hypoxic state also occur [2], on a time-scale of minutes or hours when they result from an efflux of red blood cells, or days when they are due to vascular network remodelling and angiogenesis [3].

Hypoxia is associated with increased resistance to chemo- and radiotherapy (as extensively reviewed by Rockwell et al. [4]), two commonly used clinical cancer treatments. Assessing the spatial and temporal variation in hypoxia levels could be predictive of a cancer therapy response and may therefore have a crucial role in treatment planning and adaptation [5,6]. Conventionally, oxygen needle electrodes have been used to assess hypoxia in patients, by directly measuring tissue partial oxygen pressure (pO₂) [7]. However, needle electrodes are invasive and provide only a local value, which is not representative of the whole tumour. Techniques which use conventional non-invasive imaging have been developed to attempt to infer,

not only the oxygenation levels, but also the spatial distribution of hypoxia. Several Positron Emission Tomography (PET) radiotracers are available [8–10], providing a noninvasive alternative, albeit with a relatively poor spatial resolution and high cost.

Unfortunately, the use of radioactive isotopes is also ill-suited to longitudinal studies due to radiation dose accumulation. Blood oxygenation level dependent (BOLD)-magnetic resonance imaging (MRI) [11] enables the measurement of relative blood oxygen saturation (sO₂) increase during carbogen challenge compared to air-breathing. It has been shown that these measurements are in good spatial agreement with tissue pO₂ measurements [12–14] and histological markers of hypoxia [15,16]. BOLD-MRI, however, has poor specificity for hypoxia, and does not provide absolute sO₂.

Recently, the use of combined ultrasound (US) and optical imaging techniques, such as photoacoustic imaging (PAI), has been proposed as a method of non-invasively mapping blood sO₂ [17–20]. PAI can identify the unique spectral signatures of deoxy- (Hb) and oxyhaemoglobin (HbO₂) [17]. The quantification of the local levels of each chromophore further allows mapping of blood sO₂ distribution in the tissue, defined as the ratio of HbO₂ to the total amount of haemoglobin (HbT, the sum of HbO₂ and Hb) [21].

* Corresponding author at: The Institute of Cancer Research, CCI Building, 15 Cotswold Road, SM2 5NG, Sutton, United Kingdom.

E-mail address: marcia.costa@icr.ac.uk (M. Martinho Costa).

¹ First co-authorship.

PAI has been used for hypoxia mapping pre-clinically, in subcutaneous [15,18,21–26] and brain tumours [27], showing good agreement with pimonidazole staining [18,22], an exogenous hypoxia marker [15], and gold nanorods [28], and imaging modalities, such as bioluminescence [20], high resolution and dynamic contrast enhanced US [21,23] and BOLD-MRI [24,25].

PAI provides a powerful tool for quantifying tumour blood sO_2 and has the potential of being used in clinic to predict and monitor treatment response involving changes in tumour vasculature. A potential limitation is that variability resulting from the measurement technique, or the intrinsic biological variability, may obscure changes resulting from a treatment. Primary sources of variability could be technical (system hardware, positioning of the tumour with respect to imaging transducer, data processing) and/or biological (effect of anaesthesia, tumour growth). It is known that anaesthetic agents significantly alter haemodynamic parameters. For example in mice, isoflurane, urethane, pentobarbital sodium, or ketamine-xylazine anaesthesia are known to cause substantial effects on haemodynamic parameters [29]. Such variability needs to be considered when interpreting changes in tumour vasculature in response to therapies. Joseph et al. [30] performed a technical validation study of a PAI tomography system (MSOT-inVision 256-TF, iThera Medical), demonstrating both reproducibility and repeatability of the measurements in phantoms and in vivo. They showed that the position of the test object with respect to the transducer had the greatest impact on signal repeatability. Joseph et al. also monitored the influence of inhaled isoflurane on sO_2 measurements in kidney and spleen. This present paper aims to characterise the biological variability of photoacoustic imaging measurements of Hb, HbO_2 , HbT and sO_2 in a subcutaneous head and neck tumour model, commonly hypoxic, using the same commercial PAI tomography system. Short-term intrinsic biological variability, for a period of 75 min, was tested to investigate the effect of anaesthesia on tumoural sO_2 and HbT. The tumour positions (with respect to the imaging transducer) were also altered to understand the impact on signal variability. Long-term variability in the parameters of growing tumours was assessed over a period of 6 days. Our results demonstrated the importance of assessing such tumoural baseline measurements prior to performing studies involving prediction and monitoring of treatment response, involving a change in sO_2 and HbT.

2. Methods

2.1. Tumour model and growth rates

All research was conducted under the Guidelines of Animal Welfare provided by the UK Home Office with approval from the local animal welfare and ethics board and under Helsinki Declaration of 1975.

The human head and neck squamous cell tumour model, CAL^R, used for this study is a noncommercially available cancer cell line developed at the Institute of Cancer Research [31].

Half a million cells were injected subcutaneously into the right flank of 6 week old female FOXNuⁿ¹ mice (~25 g). Animals were monitored for the development of a mass. Once palpable, tumour dimensions were measured every 2 or 3 days, in 3 orthogonal directions (length (l), width (w) and height (h)), using Vernier calipers. Tumour volume (V) was calculated assuming an ellipsoidal shape, as commonly used for subcutaneous tumours, according to Eq. (1).

$$V = \frac{1}{6} \times l \times w \times h \quad (1)$$

The volume error (V_{error}), for each individual tumour, was estimated from the derivative of an ellipsoidal volume, assuming a measurement error (E_m) of 0.5 mm in each direction, using Eq. (2).

$$V_{\text{error}} = \sqrt{\left(\left(\frac{dV}{dl} \times E_m\right)^2 + \left(\frac{dV}{dw} \times E_m\right)^2 + \left(\frac{dV}{dh} \times E_m\right)^2\right)} \quad (2)$$

Tumour dimensions are therefore presented as mean volume plus standard deviation of the estimate, based only on the accuracy of the three orthogonal dimension measurements, ignoring any deviation in shape from an ellipsoid.

Tumour growth curves were fitted to the Exponential-Linear Model for calculating tumour growth rates [32]. Two rates were calculated: α_0 is the growth rate during the exponential phase, and α_1 is the growth rate in the linear phase. For details of these calculations, see Supplementary Methods.

2.2. Photoacoustic imaging data acquisition and reconstruction

Mice were imaged using a commercially available, real time, multispectral optoacoustic tomographic (MSOT) device, inVision 256-TF small animal scanner (iThera Medical GmbH, Munich, Germany) [29]. The system has a tunable optical parametric oscillator pumped by a Q-switched Nd:YAG near-infrared laser. A 256 element, toroidally focused, ultrasound imaging transducer (4 cm radius) with a centre frequency of 5 MHz (60% bandwidth) was used to acquire the acoustic signal, resulting from the optical tissue excitation. These elements cover an angle of 270° around the tumour to create a cross-sectional image.

Tumours were first imaged (defined as Day1) when they reached a volume of approximately 200 mm³. Anaesthesia was induced using an intraperitoneal injection of midazolam:fentanyl:medetomidine (5.0:0.05:0.5 mg kg⁻¹). This anaesthetic combination is known to provide long anaesthesia times (~60 min) [33]. It is suitable for studies involving protocols which could potentially cause pain (e.g. therapies involving tissue heating) or where mice need to be re-anaesthetised multiple times over a short period (e.g. multimodality imaging, imaging-therapy studies), as will be performed by us as a part future work. Mice were placed horizontally in a holder encased in a thin (17 µm) polyvinyl chloride (PVC) film (see Supplementary Fig. S1), with their tumour facing vertically downwards, i.e. directly in the direction of the laser beam, and acoustically coupled to the membrane using ultrasound imaging gel. In order to provide acoustic coupling to the MSOT, the animal holder was completely submerged in a tank filled with 34 °C distilled water. During immersion, medical air (21% oxygen) and/or 100%-oxygen were supplied continuously to the mouse via tubing, in order to avoid asphyxiation. Imaging started approximately 5 min after placing the holder in the water tank, in order to allow the animal's body temperature to equilibrate with the water's temperature.

For acquiring the photoacoustic data, a volume of interest (VOI), containing the whole tumour was selected to avoid a large dataset. Transverse (medial-lateral direction) imaging slices were acquired at 1 mm intervals in the cranial-caudal direction. The optical imaging wavelengths used were: 700, 715, 730, 750, 760, 800, 850, and 900 nm. This wavelength range maximises the differences in Hb and HbO_2 signals. Ten signal averages per wavelength were obtained for each imaging slice.

Photoacoustic images were reconstructed using a model-based inversion algorithm [34] which was implemented in the viewMSOT software (v3.8) provided by iThera Medical.

Spectral unmixing was used to calculate the contribution of each chromophore, HbO_2 and Hb, in blood, in order to calculate the sO_2 . This is done on a pixel-by-pixel basis, using a linear regression algorithm [35]. Pixels which indicated regions where the total amount of haemoglobin is so low, or sources of noise so high, that adequate confidence in spectral recognition could not be achieved, or where the reconstruction method produced pixels with negative Hb and HbO_2 values, were set to a zero value. The software subsequently allows calculation of the mean HbO_2 and Hb signals (which includes the zero value pixels) in a user defined region of interest (ROI) which could be drawn onto the greyscale anatomical image (Fig. 1A). These mean Hb and HbO_2 values are added together to calculate the mean total haemoglobin per ROI. For any ROI the mean oxygen saturation was calculated using Eq. 3.




Fig. 1. A: Greyscale photoacoustic image obtained from optical excitation at a single wavelength (800 nm). The yellow polygon is the ROI used to delineate the tumour. B: Shows an 'oxymap' overlaid on the tumour. The 'oxymap' colour scale on the right represents the blood sO_2 calculated by the MSOT software on a pixel-by-pixel basis. Blue represents $sO_2 < 0.5$ A.U. (white), while red is $sO_2 > 0.5$ A.U. Black pixels within the ROI show where haemoglobin signals are below the noise threshold.

$$\text{mean } sO_2 = \frac{\text{mean HbO}_2}{\text{mean HbO}_2 + \text{mean Hb}} \quad (3)$$

All the parameters are unitless quantities, described in arbitrary units (A.U.), because the software does not use light fluence correction and the system response in calculations, as would be necessary to quantify the concentration (in mmol/L or mg/L) of each chromophore. The viewMSOT software also allows mapping of the spatial distribution of sO_2 calculated on a pixel-by-pixel basis, obtaining an 'oxymap' (Fig. 1B). This was not used for calculating the mean sO_2 values in ROIs because it was observed that the software did not account for the zero value pixels when calculating the mean values of sO_2 in a region of interest. These pixels are discarded from the analysis. For each 3D imaging scan, 3 slices were always chosen for the analysis of Hb, HbO₂, HbT and sO_2 .

2.3. Imaging studies

Three separate imaging studies were performed.

The first was a short-term MSOT study designed to investigate any potential effects of anaesthesia on HbT and blood sO_2 . A 3D whole tumour dataset was acquired every 5 min for 75 min, after allowing 5 min for the tumour to reach thermal equilibrium with the imaging system. Only air-breathing imaging was acquired, in order to maximise the rate (and number) of datasets that could be acquired. Measurements were acquired in 4 animals when their tumours reached a target volume of 200 mm³.

The PAI optical fluence is depth-dependent, and hence the position of tissue of interest with respect to the imaging transducer can affect the PAI measurements, as this can alter the amount of near-infrared light attenuated by overlying tissue, as well as the field intensity incident on that position. In order to study how re-positioning the animal affects measurements of blood haemoglobin and blood sO_2 , a second short term study was performed, 24 h after the first study. The same 4 animals were anaesthetised once and imaged in three consecutive sessions after being dismounted from the imaging system between each session. In addition, the tumour was placed at a slightly different position relative to the transducer each time. Whole tumour 3D datasets were acquired first under air breathing conditions which took approximately 2 min, and then under 100% oxygen breathing, after allowing 2 min for the oxygen to reach the tumour, for the same VOI, under hyperoxic conditions [25]. Oxygen breathing can be used as a contrast agent for PAI, enhancing tumour and spatial differences when vascularity is imaged using sO_2 [36]. Approximately 4 min were needed to remove the animal from the holder, reposition it and replace it.

For both short-term studies, a linear regression model was applied

to calculate an estimate of the average change in signal over time, as well as the goodness of fit between the imaging data and the model. This was obtained using the curve fitting toolbox (version 3.5.3) available in MATLAB R2016a software. To investigate the suitability of the linear model for these studies, three parameters were calculated: goodness of fit (R^2) that indicates how much of the variability of the parameter (Hb, HbO₂, HbT and sO_2) is time-dependent; p-value of the model which shows if the slope is significantly different from 0 (if p-value < 0.05); and the Sum of Squared Errors (SSE) of the prediction model that indicates the suitability of the linear model for explaining the variability behaviour of the data (the closer SSE is to 0, the better the linear fitting). The temporal variations of both the 75 min and the re-positioning study were also compared by calculating if there were statistical differences in signal change between studies, using an analysis of covariance (software: GraphPad Prism 7).

The third, a long-term study, was designed to image tumours sequentially during a period of growth. When tumours ($n = 10$) reached a volume of approximately 200 mm³, animals were imaged on 3 consecutive days ('Day 1, 2 or 3'). This volume was chosen as being suitable for future studies of cancer treatment e.g. using radiotherapy. Tumours were also imaged on day 6 in order to evaluate changes in haemoglobin and blood sO_2 during tumour growth. For this study, animals were imaged under air- and oxygen-breathing conditions.

For short- and long-term studies, three slices in each tumour, separated by 1 mm, were chosen for analysis, a central slice and the adjacent slice on either side. The mean haemoglobin and blood sO_2 values were obtained by averaging over the three whole-tumour ROIs to provide the tumour ROI-averaged Hb, HbO₂, HbT and sO_2 . For each animal, the average percentage of black pixels in the three central tumour slices was also calculated in order to evaluate the signal lost in each ROI. For the repositioning and long term studies, ΔsO_2 , i.e., the difference in blood sO_2 between air- and oxygen-breathing was also calculated, as it has been shown as a useful parameter in other PAI published literature [25,36].

2.4. Statistical analysis

The slice-, intra-tumour and inter-tumour coefficients of variation (CoVs), i.e. the ratio of standard deviation to mean, were calculated for Hb, HbO₂, HbT and sO_2 in all PAI studies. Intra- and inter-tumour CoVs of ΔsO_2 were also calculated for the repositioning and 6-day studies. The first indicates how much variation to expect between the 3 ROIs chosen for the analysis of the PAI parameters; the second the variation of the measurements for each animal and the third the variation between animals.

A paired student *t*-test was used to assess the level/degree of




Fig. 2. ROI-averaged percentage of black pixels, and Hb, HbO₂, HbT and sO₂ signals, for CAL^R tumours ($n = 4$) imaged over 75 min, during air-breathing. Error bars represent the standard deviation over 3 adjacent central tumour slices (ROIs), 1 mm apart. Solid lines represent a linear regression fitted to the data.

significance of differences in the mean Hb, HbO₂, HbT and sO₂ of CAL^R tumours during the long-term variability studies, on imaging days 1, 2, 3 and 6, using R software.

3. Results

3.1. Short term PAI variability study

3.1.1. Variation in time: 75 min

For the first short-term study, aimed at investigating the effect of anaesthesia over 75 min in the photoacoustic imaging measurements, four animals were imaged. Fig. 2 shows the short term variation in the ROI-averaged percentage of black pixels and average Hb, HbO₂, HbT and sO₂, over the three tumour slices per animal. A trend of a decrease in the percentage of black pixels (i.e. those with undetectable levels of haemoglobin), is observed for animals 1, 2 and 4 after the initial 10 min of imaging, after an initial increase between 5 and 10 min. Animal 3 has a more constant percentage of black pixels compared to the remaining 3

animals, over the whole imaging time. An increase in Hb and HbO₂ (and therefore HbT), and sO₂ over the whole time period was observed for all tumours, except for the sO₂ values measured for animal 3.

Fig. 3 shows an example of the oxygenation maps obtained for this study. A radial sO₂ gradient, but over time, more white and pink regions (blood sO₂ ≥ 0.5) extend towards the middle of the tumour, and the margins attached to the body shift from dark blue to light blue, consistent with the indication of increased blood sO₂.

The different change rates are shown in Table 1. This summarises the ROI-averaged rate of change of Hb, HbO₂, HbT, sO₂ and percentage of black pixels (%BP), as well as the goodness of fit (R^2) and the sum of squares of error (SSE) of the linear regression used to calculate these rates of signal change. Animals 1 and 2 had a faster increase in Hb (and HbO₂) than animals 3 and 4. This was reflected in the rate of HbT over 75 min. While for animals 1 and 2, the increase in HbT was $> 0.027 \text{ min}^{-1}$, for animals 3 and 4, this rate was $< 0.015 \text{ min}^{-1}$. Animals 1 and 2 also had a faster decrease in %BP (-0.278 min^{-1} and -0.146 min^{-1} , respectively) compared to animals 3 and 4




Fig. 3. sO_2 distributions or 'oxymaps' of one tumour, at 5, 15, 30, 45, 60 and 75 min after placing the animal in the tank. The 'oxymaps' are shown as overlays on greyscale photoacoustic images, of the central slice of each tumour. B: body; W: water. Yellow bar represents a 10 mm size scale.

(-0.0284 min^{-1} and -0.081 min^{-1} , respectively).

Table 1 also shows the increase in blood sO_2 . Animals 1, 2 and 4, had similar increases in blood sO_2 (range: 0.0027–0.0031), but for animal 3, the blood sO_2 rate of change was negligible, 0.00025 (3.148e-05, 0.00047), with $R^2 = 0.267$. This is a consequence of a similar increase in Hb (0.0079 min^{-1}) and HbO_2 (0.0071 min^{-1}).

Table 1

Rate of change of ROI-averaged Hb, HbO_2 , HbT, sO_2 and percentage of black pixels (%BP) signal during the short-term (75 min) longitudinal study. The goodness of fit, R^2 , indicates how much of the signal variability is time dependent and the p-value whether the signal change (slope of the linear model) is significantly different from zero. The SSE reflects how similar the predicted values and measured data are, i.e. the closest SSE is to zero, the better the linear fit.

Animal		Signal change, min^{-1} (95% CI)	R^2	p-value	SSE
1	Hb HbO_2	0.013 (0.012, 0.015)	0.968 0.932	< 0.001	0.037 0.117
	HbT	0.016 (0.013, 0.018)	0.976	< 0.001	0.142
		0.030 (0.027, 0.033)		< 0.001	
	sO_2	0.0031 (0.0025, 0.0038)	0.895	< 0.001	0.007
	%BP	-0.278 (-0.392, -0.163)	0.679	< 0.001	255
2	Hb HbO_2	0.013 (0.013, 0.014)	0.981 0.995	< 0.001	0.020 0.006
	HbT	0.014 (0.013, 0.015)	0.995	< 0.001	0.027
		0.027 (0.026, 0.028)		< 0.001	
	sO_2	0.0027 (0.0023, 0.0032)	0.923	< 0.001	0.004
	%BP	-0.146 (-0.203, -0.0896)	0.704	< 0.001	63
3	Hb HbO_2	0.0079 (0.0066, 0.0091)	0.930 0.934	< 0.001	0.030 0.023
	HbT	0.0071 (0.0060, 0.0082)	0.938	< 0.001	0.096
		0.015 (0.013, 0.017)		< 0.001	
	sO_2	0.00025 (3.148e-05, 0.00047)	0.267	0.049	0.001
	%BP	-0.0284 (-0.037, -0.020)	0.799	< 0.001	1
4	Hb HbO_2	0.0047 (0.0040, 0.0054)	0.940 0.895	< 0.001	0.009 0.017
	HbT	0.0047 (0.0038, 0.0057)	0.940	< 0.001	0.039
		0.0098 (0.0084, 0.011)		< 0.001	
	sO_2	0.0029 (0.0022, 0.0035)	0.857	< 0.001	0.009
	%BP	-0.081 (-0.118, -0.043)	0.622	< 0.001	28

The average slice-CoV, intra- and inter-tumour CoVs in ROI-averaged Hb, HbO_2 , HbT and sO_2 , over the 75 min acquisition for each animal, are summarised in Table S1. Overall, the intra-tumour CoV was higher for the haemoglobin components (Hb: $22.5 \pm 6.0\%$; HbO_2 : $40.2 \pm 13.9\%$; HbT: $22.9 \pm 9.2\%$) than for sO_2 ($16.0 \pm 8.4\%$). The slice-CoV, indicative of the variation of photoacoustic imaging parameters, in the 3 ROIs chosen for each tumour, was lowest for all the parameters ($< 13.9 \pm 7.4\%$) compared to the intra-tumour CoV.

The inter-tumour CoV calculated for this study was $20.9 \pm 3.1\%$ for Hb, $46.4 \pm 12.4\%$ for HbO_2 , $28.6 \pm 2.3\%$ for HbT and $21.8 \pm 10.9\%$ for sO_2 . The largest variation was consistently measured for HbO_2 . These results show that, for the short-term longitudinal study, inter- and intra-tumour CoV were similar, showing a high variability is expected for each animal when imaged over 75 min.

3.1.2. Re-positioning study

The results for the study on the effect of repositioning 4 animals three times in close succession in the photoacoustic system are shown in Figs. 4 and 5. The trends for air- and oxygen-breathing were similar, so the results for air-breathing are shown here and the results for oxygen-breathing are in the Supplementary material (Fig. S2 and Tables S2–3). The 'oxymap' of the central tumour slice for each mounting position for each CAL^R tumour is shown overlain on greyscale anatomical images in Fig. 4. The images suggest a blood sO_2 gradient radially into the tumour, ie, the margin below the skin tends to have higher blood sO_2 , compared to centre and margin attached to the mouse flank. The shapes and sizes of tumours also differ between positions. On the bottom row, it is possible to see that the blood sO_2 of animal 4 is low, and in position 2, the 'oxymap' of the central slice of the tumour shows an atypically large region of black pixels (41%).

Following the changes observed in the 'oxymaps' in Fig. 4, the temporal changes in the ROI-averaged Hb, HbO_2 , HbT, sO_2 and percentage of black pixels, were analysed, in order to investigate whether re-positioning had an additive effect to the time the animal is under anaesthesia in the temporal variability of the parameters analysed.

Fig. 5 shows the ROI-averaged percentage of black pixels for each animal, in each of the three imaging positions, for the 3 central slices. While there was some variations between animals and different positions, for the majority of the tumours the mean percentage of black pixels (undetectable haemoglobin levels) was $< 19\%$. Fig. 5 also shows that re-positioning the animals resulted in significantly different




Fig. 4. A: Diagram for the re-positioning of the animal. Each air-breathing imaging session started at approximately 5, 20 and 35 min after placing the animal in the water tank of the MSOT system. Air-breathing imaging takes approximately 2 min. The air is then changed for 100%-O₂, for 2 min and the same tumour region is re-imaged for approximately 2 min again, during O₂-breathing. B: sO₂ distributions or 'oxymaps' of 4 CAL^R tumours, positioned differently by remounting the animals 3 times in the MSOT tank with the minimum time interval between each imaging session. The 'oxymaps' are shown as overlays on greyscale photoacoustic images, of the central slice of each tumour. B: body; W: water. Yellow bar represents a 10 mm size scale.

measurements of haemoglobin content and blood sO₂ levels. A trend for an increase in ROI-averaged Hb, HbO₂ and HbT was observed for most animals over time, independent of the starting and ending angle of the tumour relative to the transducer. ROI-averaged blood sO₂ tended to increase for animals 3 and 4 but remain more constant for animals 1 and 2. The Δ sO₂ values tended to decrease over time, apart from animal 3.

The quantification of the changes in signal, both for the individual haemoglobin components, blood sO₂ and percentage of black pixels, is shown in Table 2. As observed in the 75 min imaging study, a trend for an increase in Hb ($> 0.0034 \text{ min}^{-1}$), HbO₂ ($> 0.0050 \text{ min}^{-1}$) and HbT ($> 0.0084 \text{ min}^{-1}$) was observed over time. The p-values in Table 2 show that the slopes, i.e. changes in signal over time, for Hb, HbO₂, HbT and SO₂, were not significantly different from zero.

No significant differences were found between the (temporal) signal change calculated for the repositioning study and that obtained for the

longitudinal (75 min) study, for ROI averaged Hb, HbO₂, HbT and sO₂, apart for the HbT parameter for animal 2. Figs. S3–S5 show the longitudinal and re-positioning data for Hb, HbO₂, HbT and SO₂, for each animal, plotted in the same figure, and the p-values showing the similarity of the slopes, i.e. if pvalue < 0.05 the temporal change in signal was significantly different between the 75 min and re-positioning studies.

The slice- and intra-tumour CoVs for ROI-averaged Hb, HbO₂, HbT and sO₂, are summarised in Table S2. The intra-tumour CoV measurement of animal four, excluding position 2, where 46% of signal was lost, is also shown. As was seen for the 75-minute study, the intra-tumour CoVs for measurements acquired after re-positioning the animals was higher for the haemoglobin components (Hb: $22.0 \pm 6.0\%$; HbO₂: $40.0 \pm 11.0\%$; HbT: $28.1 \pm 5.1\%$) than for blood sO₂ ($22.0 \pm 21.2\%$ and $15.0 \pm 11.3\%$ with and without considering position 2 imaging for animal 4, respectively). As for the Δ sO₂ value, the intra-CoV was of




Fig. 5. ROI-averaged percentage of black pixel, and Hb, HbO₂, HbT, blood sO₂ and ΔsO₂ signals, for CAL^R tumours (n = 4) imaged after being removed and repositioned in the tank three times, during air-breathing. Error bars represent the standard deviation over 3 adjacent central tumour slices, 1 mm apart. Solid lines represent a linear regression fitted to the data.

$30.3 \pm 11.3\%$. The slice-CoV was also lower ($19.4 \pm 18.4\%$ including animal 4, position 2 imaging) than the intra-tumour CoV.

The inter-CoV calculated was $25.8 \pm 16.4\%$ for the average Hb, $45.6 \pm 19.6\%$ for the average HbO₂, $30.6 \pm 15.6\%$ for the average HbT and $26.5 \pm 8.3\%$ for the average sO₂. Excluding that data point, the inter-CoV calculated was of $20.4 \pm 16.4\%$ for the average Hb, $33.2 \pm 6.4\%$ for the average HbO₂, $22.7 \pm 6.8\%$ for the average HbT and $13.0 \pm 13.2\%$ for the average sO₂. The inter-CoV for ΔsO₂ value was high ($57.3 \pm 18.6\%$).

3.2. Variation during tumour growth, 6 day study

For the long-term study, 10 CAL^R tumours were imaged. The ROI-

averaged Hb, HbO₂, HbT, blood sO₂ and ΔsO₂ from 3 central slices per tumour, measured during air-breathing and oxygen-breathing, for the long term (6 day) variability study (total of 4 imaging sessions) are shown in Figs. S7–S9.

From this data, the inter- and intra-tumour CoV for air-breathing photoacoustic imaging, for 4 imaging sessions acquired over 6 days, were calculated and are summarised in Tables S4 and S5. As was found for the short term variability studies, the intra- and inter-tumour CoVs for the sO₂ parameter were lower ($7.5 \pm 2.5\%$ and $13.1 \pm 3.2\%$, respectively) than for the haemoglobin and ΔsO₂ parameters (range $19.3 \pm 8.7\%$ – $39.7 \pm 5.6\%$).

Table 2

Rate of change of ROI-averaged Hb, HbO₂, HbT, blood sO₂, ΔsO₂ and percentage of black pixels (%BP) signal during the re-positioning study (air-breathing). The goodness of fit, R², indicates how much of the signal variability is time dependent and the p-value if the signal change (slope of the linear model) is significantly different from zero. The SSE reflects how similar the predicted values and measured data are, i.e. the closest SSE is to zero, the better the linear fit.

Animal		Signal change, min-1 (95% CI)	R2	p-value	SSE
1	HbT	0.030 (-0.077, 0.14)	0.923	0.179	0.031 22
	%BP	-0.582 (-3.38, 2.21)	0.875	0.231	0.003
	Hb	0.014 (-0.019, 0.047)	0.966	0.120	
	HbO ₂	0.015 (-0.058, 0.089)	0.874	0.230	0.015
	sO ₂	0.0051 (-0.034, 0.044)	0.738	0.340	0.004
2	ΔsO ₂	-0.0014 (-0.036, 0.033)	0.216	0.692	0.003
	HbT	0.019 (-0.085, 0.12)	0.841	0.262	0.030 7
	%BP	-0.162 (-1.79, 1.47)	0.612	0.428	0.008
	Hb	0.0094 (-0.043, 0.062)	0.837	0.265	
	HbO ₂	0.0094 (-0.042, 0.060)	0.846	0.256	0.007
3	sO ₂	0.0018 (-0.0055, 0.0092)	0.911	0.188	< 0.001
	ΔsO ₂	-0.0013 (-0.0027, 9.34e-05)	0.993	0.057	5.79e-06
	HbT	0.022 (-0.10, 0.15)	0.829	0.271	0.043
	%BP	0.0071 (-0.490, 0.504)	0.031	0.887	0.688
	Hb	0.012 (-0.079, 0.10)	0.742	0.339	0.023
4	HbO ₂	0.0096 (-0.025, 0.044)	0.927	0.174	0.003
	sO ₂	0.00041 (-0.010, 0.011)	0.189	0.018	< 0.001
	ΔsO ₂	0.0013 (-0.0067, 0.0093)	0.804	0.291	1.86e-04
	HbT %BP	0.0084 (-0.20, 0.22)	0.207	0.700	0.122 1062
		0.204 (-19.3, 19.7)	0.017	0.917	
	Hb	0.0034 (-0.11, 0.11)	0.136	0.762	0.033
	HbO ₂	0.0050 (-0.096, 0.11)	0.289	0.639	0.028
	sO ₂	0.0031 (-0.090, 0.096)	0.153	0.155	0.024
	ΔsO ₂	-0.00024 (-0.011, 0.011)	0.071	0.829	3.40e-04

3.3. Tumour growth rate

Growth rates calculated for ten CAL^R tumours used in the longitudinal study are shown in Table 3. The individual fitted growth curves, as well as the exponential-linear model fitting, are shown in Fig. 6. The uncertainties (95% confidence intervals) are large and hence no statistically significant differences were found between individual tumour growth rates. The goodness of fit, R², for the majority of the tumours (N = 8) was ≥ 0.88, suggesting good agreement between the exponential-linear model and the data. Animals CAL^R-1 and CAL^R-8, had abnormally low fits to the model. CAL^R-1 ulcerated, which can affect the tumour growth (see Fig. 6). Fig. 6 shows stagnated tumour growth (108 ± 18 mm³ to 123 ± 20 mm³) between days 12–20 after tumour implantation for CAL^R-8.

Table 3 shows that the time at which tumour growth changed from exponential to linear varied from 2 to 10 days after tumour implant. Based on these results and the growth curves shown in Fig. 6, all

photoacoustic imaging acquired for this study was performed during the linear growth phase. In order to investigate whether these changes were related to change in volume over time (ΔV), calculated using raw caliper volume measurements, or linear rate of tumour growth (α₁), estimated using the exponential-linear model, the relationship between these parameters and the percentage difference in sO₂ between day 6 and day 1 was investigated and is shown in Fig. 7. A good negative correlation between the percentage difference in sO₂ and both ΔV and α₁, is seen, during oxygen-breathing, i.e. the larger the decrease in sO₂ (oxygen-breathing), the faster the tumour was growing. Air-breathing data is shown in Fig. S10.

4. Discussion

The main objective of this paper was to explore the variation of the blood sO₂, HbO₂, Hb and HbT parameters in untreated subcutaneous head and neck tumours measured with a tomographic photoacoustic

Table 3

Exponential (α₀) and linear (α₁) growth rates, and time after implantation for transition between exponential and linear phase, τ, for 10 CAL^R tumours, including the goodness of fit (R²) of the exponential-linear model to the growth curves.

Mouse	α ₀ (day ⁻¹)	95% confidence interval for α ₀	α ₁ (mm ³ .day ⁻¹)	95% confidence interval for α ₁	τ (days after tumour implant)	Goodness of fit (R ²)
CAL ^R -1	0.55	[0.24; 0.85]	23	[0.48; 45]	5	0.77
CAL ^R -2	0.53	[0.41; 0.65]	46	[29; 63]	6	0.92
CAL ^R -3	0.48	[0.28; 0.68]	11	[8; 14]	5	0.90
CAL ^R -4	0.48	[0.36; 0.60]	10	[9; 12]	5	0.95
CAL ^R -5	0.48	[0.36; 0.60]	48	[16; 79]	6	0.88
CAL ^R -6	0.66	[0.52; 0.81]	55	[38; 72]	4	0.97
CAL ^R -7	0.50	[0.43; 0.56]	26	[21; 32]	5	0.99
CAL ^R -8	0.33	[0.26; 0.39]	49	[0; 110]	10	0.64
CAL ^R -9	1.2	[0; 2.7]	10	[7; 12]	2	0.95
CAL ^R -10	0.77	[0.22; 1.3]	30	[18; 42]	3	0.96




Fig. 6. CAL^R tumour volume, as measured by calipers (blue circles). Error bars represent tumour volume error, as described by Eq. 2. The exponential-linear fitted model is shown by the blue full line with 95% confidence intervals (dashed red lines).

system, with time, over short (minutes-hours) and long periods (several days), and with position of the animals in the imaging cradle. From these studies, it was possible to quantify the variability due to anaesthesia, tumour growth and re-positioning. This baseline information is required for assessing the significance of any changes in these characteristics that may be related to response to treatment, in future studies of the effects of radiotherapy and/or HIFU.

Initially, short-term variability of the PAI parameters was assessed. The photoacoustic signal variability over 75 min was measured to

investigate whether the injectable anaesthesia could affect haemoglobin and blood sO_2 measured in tumours. Fig. 2 shows a decreasing trend in black pixels, regions where HbT is too low to be measured, after the first 10 min of imaging. Shah et al. [23] showed, by co-registration of PAI (using this system) and microbubble contrast-enhanced ultrasound images, that the black regions in tumours (in mice) did not lack perfusion, although they typically exhibited lower levels of perfusion and later microbubble arrival than other regions within the tumour. The MSOT and the software available at the moment




Fig. 7. Correlation between rate of change in volume between day 1 and 6 of imaging, ΔV , or linear growth rate, α_1 , and the percentage difference in sO_2 between days 1 and 6 of imaging for 8 CAL^R tumours, for oxygen-breathing measurements.

are still 1st generation and efforts are being made to improve the detection of HbT in order to eliminate the occurrence of black pixels.

During the 75 min in which in the percentage of black pixels tended to decrease, an increase in Hb, HbO₂ and HbT (Fig. 2 and Table 1) was measured, resulting in increased blood sO_2 for 3 out of 4 animals. These results suggest peripheral vasodilation. The combination of medetomidine, fentanyl and midazolam used for this study has been shown to cause a significant increase in blood pressure in rabbits, rats, and mice, which could arise from an increase in vascular resistance or peripheral vasoconstriction [33,37,38]. However, it is well-known that the cardiovascular effects of the combination of these anaesthetic agents vary in different species [39] and to the authors' knowledge, there have been no reports on its effect in female FOXnuⁿ¹ mice. Furthermore, there is a trend for decrease in sO_2 and decrease in body temperature. Our results suggest that these are not the cardiovascular effects we are measuring. The increase in HbT and sO_2 in our study can be due to a cardiovascular effect of the anaesthetic agent combination, due to an influence of the hydrodynamic pressure when the animal is enveloped in a plastic film and submerged inside the water tank, or due to an influence of the compression of the tumour due to the animal's body weight, which possibly stops blood outflow from the tumour. All these factors could have contributed to the trend that was observed and further work is necessary to understand its source. Indeed, a study of the effects of the MSOT experimental setup on the animal's tissue and blood gases would be quite important, but it is not possible to perform with the current hardware.

The trend for an increase in haemoglobin was observed during the whole duration of imaging session, so the signal does not stabilise during an acceptable period of anaesthesia for a small animal. Therefore, this baseline change in signal needs to be considered in future studies, as it is not possible to wait for long enough for a stable signal to be seen before starting imaging the animal.

The inter- and intra-tumour CoVs (as shown in Table S1) were similar in this study, $> 16.0 \pm 8.4\%$ and $> 20.9 \pm 3.1\%$, respectively, for the parameters analysed: Hb, HbO₂, HbT and sO_2 . This reflects a high variation in the measured signal of each animal, probably due to the increasing trend in haemoglobin and blood sO_2 over time. Joseph et al. (2017) [30] studied the repeatability and reproducibility of PAI with the same system as that used here in the left kidney and spleen of 8–12 week old mice ($n = 7$), acquiring images over a period of 90 min, under isoflurane anaesthesia. Interestingly, with this anaesthetic, the authors found a steady increasing trend in HbT and blood sO_2 over the 90 min imaging acquisition time. The group reported that the intra-organ CoVs for haemoglobin (Hb, HbO₂ and HbT, measurements averaged over a single ROI) for spleen was below 16.4 and for kidney below 18.5, while for sO_2 these values dropped to 3.9 and 3.4,

respectively. The CoVs measured in this paper during 75 min of imaging in subcutaneous tumours were higher than those reported in spleen and kidney, although it is not possible to compare the uncertainties in the measurements. In the experiment conducted by Joseph et al [30], the organs (spleen and left kidney) were located deep within the animal's body, so there was likely to be minimal compression of their blood supply due to mounting in the system, unlike the situation for subcutaneous tumour, located superficially. This is in addition to the deficient vascular supply that renders tumours prone to 'cyclic' hypoxia [2], which can affect the measurements of haemoglobin and oxygen saturation.

In the second study reported here, the effects of re-positioning the animal three times during one imaging session were analysed. Fig. 4 shows that the shape of the tumour may vary considerably during re-positioning of the animal, changing the size of the tumour-ROI used for analysis. Subcutaneous tumours, besides being subject to compression due to the animal's body weight acting against buoyancy, as well as due to hydrostatic pressure, can move relative to underlying anatomy as the skin can be highly mobile. Therefore, during longitudinal studies it would be important for the user to place the animal and tumour in the same position relative to the MSOT mouse holder. From Fig. 4, it is possible to observe differences in the 'oxymaps' depending on the position of the animal, which can result in differences in the distribution and intensity of blue/red pixels. A radial gradient in blood sO_2 was observed for all animals (as well as in the 75 min study, Fig. 3). This might be due to lack of light fluence correction, ie, the MSOT system does not take in consideration changes in light absorption with depth, although efforts are being made to implement this correction [39]. In mouse 4, position 2 resulted in an atypically high number of black pixels (46%), with correspondingly uncharacteristically low levels of Hb, HbT and sO_2 . However, this was observed in only one imaging scan, for one animal out of twelve, so the likelihood of this type of artefact is very low.

In order to investigate whether the differences in 'oxymaps' during the re-positioning study also resulted in significant differences in ROI-averaged photoacoustic imaging measurements (Hb, HbO₂, HbT and sO_2) over time, the temporal changes in these measurements were calculated. A trend for an increase in the haemoglobin components amount was also observed, as in the 75-minute study. Animal 3 exhibited no trend in levels of sO_2 compared to the other two animals, consistent with the observations of the sequential imaging for a period of 75 min. Table 2 shows that for this study, the p-values were > 0.05 so the slopes (change in signal) were not significantly different from zero. This is likely to be due to the low ($n = 3$ positions) number of points, per animal.

From Figs. S3–S5, it is also possible to observe that there were no

significant differences between the various positions, for the slopes representing the variation over the 75 min of the imaging study. The imaging for animal 4, in position 2 that resulted in a large number of black pixels, increased the inter- and intra-tumour CoV for the re-positioning study. However, the majority of the signal in this imaging scan was lost, so it is not possible to know if this decrease is a result of changes in the tumour or simply an artefact due to the signal loss.

The inter- and intra-tumour CoV for the CAL^R tumours due the re-positioning of the animal (Table S2) were $> 22.0 \pm 21.2\%$ and $> 26.5 \pm 8.3\%$, respectively, for all the parameters (Hb, HbO₂, HbT and sO₂), and hence similar to those obtained for the study without re-positioning the animal (see Table S1), over a 75-minute period, apart from animal 4. This also suggests that anaesthesia is the main experimental factor that contributes for the temporal variability of the signal, as found by Joseph et al. [30].

The intra- and inter-tumour CoVs for the 6 day imaging study were $> 19.3 \pm 8.7\%$ and $> 27.0 \pm 4.1\%$, respectively, for the haemoglobin parameters (Hb, HbO₂ and HbT). The sO₂ parameter showed a lower intra-tumour CoV ($7.5 \pm 2.5\%$) in the long term studies, in comparison to Hb, HbO₂ and HbT. Joseph et al. [30] also demonstrated, by imaging the animals on 3 consecutive days, that while the sO₂ was constant over time in kidney (maintained between 0.8 and 0.7) and spleen (maintained between 0.6 and 0.8), for HbT the variation was larger (between 25–16 A.U. and 9–13 A.U. for spleen and left kidney, respectively). These studies suggest that variation in blood sO₂ is expected to be lower than that for haemoglobin. Also, the intra-tumour blood sO₂ variability is lower for the long-term study, over 6 days, compared to that obtained for the 75 min ($16.0 \pm 8.4\%$) and re-positioning ($22.0 \pm 21.2\%$) studies, once more showing that time under anaesthesia per imaging session should be minimised. The ΔsO_2 CoVs were high ($> 30\%$) in both the 6-day and repositioning study, hence we did not consider this parameter to be as reliable as in Joseph et al. [30] study.

In order to assess whether there was any dependence of tumour blood sO₂ on growth, the growth rates of the 10 CAL^R tumours during two different growth stages, were calculated using the exponential-linear model. The goodness of fit showed a good correlation ($R^2 > 0.8$) between the model and 8 datasets. Of the two animals omitted from analysis, one of the tumours became ulcerated, which is known to introduce an error in tumour measurement [41] and the other animal showed an unexpected delay in tumour growth. Fig. 7 shows a good linear relationship between the linear growth rate and the variation in sO₂ ($R^2 = 0.72$, $n = 8$), during oxygen-breathing. A negative linear relationship was found between the rate of change in volume calculated just for the 6 days of imaging and percentage change in sO₂ ($R^2 = 0.67$). Tumours that grew faster ($n = 5$) during the linear phase ($\alpha_1 > 20 \text{ mm} \cdot \text{day}^{-1}$) had a decrease in sO₂ [range of -10% to -56%] between days 1 and 6 of imaging, probably because they outgrew their blood supply before new vasculature could be formed. Slower growing tumours ($n = 3$) exhibited an increase or no change in sO₂ [$+12\%$ and -1%], possibly because angiogenesis was occurring at a rate similar to the tumour growth rate. Interestingly, Tomaszewski et al. [40] used oxygen enhanced (OE)-PAI, to visualise the spatiotemporal heterogeneity of tumour vascular function in a poorly differentiated and aggressive prostate tumour model, PC3. They showed that sO₂ (while O₂ breathing) and ΔsO_2 also decreased with tumour growth, from a 30 mm^3 volume to time of culling. The CAL^R model used for this project has also been shown to develop rapidly and become hypoxic [40]. This observation showed that tumours of the same cell-line, although inoculated on the same day in the same-mouse strain, grow differently and this inherent biological variability should be considered for studies involving long term assessment of vasculature changes in response to a therapy.

A limitation of this study is that it evaluated the baseline variations in the photoacoustic signal for only one tumour type, a subcutaneous head and neck tumour model. Other tumour types might show different variation. For example, Tomaszewski et al. [36] showed that two prostate tumour models, PC3 and LNCaP, exhibited different haemodynamic behaviour, as assessed by PAI.

5. Conclusions

This paper documents the variation in haemoglobin (Hb, HbO₂ and HbT) and oxygen saturation over short (up to 75 min) and long (6 days) periods, and the variation with repositioning of the animal, in untreated subcutaneous head and neck tumours in nude mice. Time under anaesthesia is the largest source of temporal variability in the photoacoustic signal. To perform inter- and intra-animal comparison in longitudinal studies, for example when assessing the effects of treatment, ideally the imaging should be started at a fixed time point after anaesthesia and, if possible, sham-treated animals should be imaged at the same time points as the treated animals.

Positioning of the animal was found to influence image quality in a limited number of animals; when reconstruction artefacts or an unexpected absence in PAI signal are observed during the preview of the scan, the animal can be removed and re-positioned to obtain improved PAI signal. With a carefully planned experimental protocol, photoacoustic imaging could be used for assessing changes in tumour haemoglobin and oxygenation in longitudinal studies, including those designed to assess cancer therapies that may affect vasculature and, consequently, tumour oxygenation.

Data availability

All data and/or analysis performed in this study are available from the corresponding author on request.

Conflict of interest

The authors declare that there are no conflict of interest.

Acknowledgements

We gratefully thank the Portuguese Foundation for Science and Technology (PhD grant SFRH/BD/90250/2012) for funding part of this project. We further acknowledge funding from the EPSRC (strategic equipment grant EP/NO15266/1) and the Cancer Research UK Cancer Imaging Centre at the Institute of Cancer Research (grant C1060/A16464). We would also like to thank the Focused Ultrasound Foundation for their support of our Centre of Excellence.

Appendix A. Supplementary data


Supplementary material related to this article can be found, in the online version, at doi:<https://doi.org/10.1016/j.pacs.2018.12.002>.

References


- [1] B.L. Krock, N. Skuli, M.C. Simon, Hypoxia-induced angiogenesis: good and evil, *Genes Cancer* 2 (12) (2011) 1117–1133.
- [2] C. Michiels, C. Tellier, O. Feron, Cycling hypoxia: a key feature of the tumor microenvironment, *Biochim. Biophys. Acta* 1866 (1) (2016) 76–86.
- [3] M.W. Dewhirst, Relationships between cycling hypoxia, HIF-1, angiogenesis and oxidative stress, *Radiat. Res.* 172 (6) (2009) 653–665.
- [4] S. Rockwell, et al., Hypoxia and radiation therapy: past history, ongoing research, and future promise, *Curr. Mol. Med.* 9 (4) (2009) 442–458.
- [5] H. Harada, [Hypoxia-inducible factors as molecular targets for cancer therapy], *Nihon Rinsho* 70 (Suppl 8) (2012) 113–117.

- [6] M. Yoshimura, et al., Microenvironment and radiation therapy, *Biomed. Res. Int.* 2013 (2013) 685308.
- [7] M. Busk, et al., Imaging hypoxia in xenografted and murine tumors with 18Ffluoroazomycin arabinoside: a comparative study involving microPET, autoradiography, PO2-polarography, and fluorescence microscopy, *Int. J. Radiat. Oncol. Biol. Phys.* 70 (4) (2008) 1202–1212.
- [8] S.G. Peeters, et al., A comparative study of the hypoxia PET tracers [(1)(8)F]HX4, [(1)(8)F]FAZA, and [(1)(8)F]FMISO in a preclinical tumor model, *Int. J. Radiat. Oncol. Biol. Phys.* 91 (2) (2015) 351–359.
- [9] S.G. Peeters, et al., Current preclinical and clinical applications of hypoxia PET imaging using 2-nitroimidazoles, *Q. J. Nucl. Med. Mol. Imaging* 59 (1) (2015) 39–57.
- [10] E. Lopci, et al., Imaging acute spinal myelitis with 18F-FDG PET/CT, *Eur. J. Nucl. Med. Mol. Imaging* 41 (2) (2014) 399–400.
- [11] J.L. Tatum, et al., Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy, *Int. J. Radiat. Biol.* 82 (10) (2006) 699–757.
- [12] D. Zhao, et al., Comparison of 1H blood oxygen level-dependent (BOLD) and 19F MRI to investigate tumor oxygenation, *Magn. Reson. Med.* 62 (2) (2009) 357–364.
- [13] S. Chopra, et al., Comparing oxygen-sensitive MRI (BOLD R2*) with oxygen electrode measurements: a pilot study in men with prostate cancer, *Int. J. Radiat. Biol.* 85 (9) (2009) 805–813.
- [14] C. Baudelet, B. Gallez, How does blood oxygen level-dependent (BOLD) contrast correlate with oxygen partial pressure (pO2) inside tumors? *Magn. Reson. Med.* 48 (6) (2002) 980–986.
- [15] P.J. Hoskin, et al., Hypoxia in prostate cancer: correlation of BOLD-MRI with pimonidazole immunohistochemistry-initial observations, *Int. J. Radiat. Oncol. Biol. Phys.* 68 (4) (2007) 1065–1071.
- [16] P. Prasad, et al., Evaluation of renal hypoxia in diabetic mice by BOLD MRI, *Invest. Radiol.* 45 (12) (2010) 819–822.
- [17] P. Beard, Biomedical photoacoustic imaging, *Interface Focus* 1 (4) (2011) 602–631.
- [18] M. Gerling, et al., Real-time assessment of tissue hypoxia in vivo with combined photoacoustics and high-frequency ultrasound, *Theranostics* 4 (6) (2014) 604–613.
- [19] J. Laufer, et al., In vivo preclinical photoacoustic imaging of tumor vasculature development and therapy, *J. Biomed. Opt.* 17 (5) (2012) 056016.
- [20] A. Tarutis, V. Ntziachristos, Advances in real-time multispectral optoacoustic imaging and its applications, *Nat. Photonics* 9 (2015) 219–227.
- [21] F. Raes, et al., High resolution ultrasound and photoacoustic imaging of orthotopic lung cancer in mice: new perspectives for onco-pharmacology, *PLoS One* 11 (4) (2016) e0153532.
- [22] S. Mallidi, et al., Prediction of tumor recurrence and therapy monitoring using ultrasound-guided photoacoustic imaging, *Theranostics* 5 (3) (2015) 289301.
- [23] A. Shah, et al., Value of combining dynamic contrast enhanced ultrasound and optoacoustic tomography for hypoxia imaging, *Photoacoustics* 8 (2017) 15–27.
- [24] L.J. Rich, M. Seshadri, Photoacoustic imaging of vascular hemodynamics: validation with blood oxygenation level-dependent MR imaging, *Radiology* 275 (1) (2015) 110–118.
- [25] L.J. Rich, M. Seshadri, Photoacoustic monitoring of tumor and normal tissue response to radiation, *Sci. Rep.* 6 (2016) 21237.
- [26] V. Ermolayev, et al., Simultaneous visualization of tumor oxygenation, neovascularization and contrast agent perfusion by real-time three-dimensional optoacoustic tomography, *Eur. Radiol.* 26 (6) (2016) 1843–1851.
- [27] M.L. Li, et al., Simultaneous molecular and hypoxia imaging of brain tumors in vivo using spectroscopic photoacoustic tomography, *Proc. IEEE* 96 (3) (2008) 481–489.
- [28] E. Herzog, et al., Optical imaging of cancer heterogeneity with multispectral optoacoustic tomography, *Radiology* 263 (2) (2012) 461–468.
- [29] B.J.A. Janssen, et al., Effects of anesthetics on systemic hemodynamics in mice, *Front. Oncol.* 287 (4) (2014) 1618–1624.
- [30] J. Joseph, et al., Evaluation of precision in optoacoustic tomography for preclinical imaging in living subjects, *J. Nucl. Med.* 58 (5) (2017) 807–814.
- [31] C. Box, et al., A novel serum protein signature associated with resistance to epidermal growth factor receptor tyrosine kinase inhibitors in head and neck squamous cell carcinoma, *Eur. J. Cancer* 49 (11) (2013) 2512–2521.
- [32] S. Benzekry, et al., Classical mathematical models for description and prediction of experimental tumor growth, *PLoS Comput. Biol.* 10 (8) (2014) e1003800.
- [33] T. Fleischmann, et al., Injection anaesthesia with fentanyl-midazolam-medetomidine in adult female mice: importance of antagonization and perioperative care, *Lab. Anim.* 50 (4) (2016) 264–274.
- [34] A. Rosenthal, D. Razansky, V. Ntziachristos, Fast semi-analytical model-based acoustic inversion for quantitative optoacoustic tomography, *IEEE Trans. Med. Imaging* 29 (6) (2010) 1275–1285.
- [35] M. Kneipp, et al., Functional real-time optoacoustic imaging of middle cerebral artery occlusion in mice, *PLoS One* 9 (4) (2014) e96118.
- [36] M.R. Tomaszewski, et al., Oxygen enhanced optoacoustic tomography (OE-OT) reveals vascular dynamics in murine models of prostate cancer, *Theranostics* 7 (11) (2017) 2900–2913.
- [37] C. Baumgartner, et al., Effects of medetomidine-midazolam-fentanyl IV bolus injections and its reversal by specific antagonists on cardiovascular function in rabbits, *Can. J. Vet. Res.* 74 (4) (2010) 286–298.
- [38] M. Albrecht, et al., Influence of repeated anaesthesia on physiological parameters in male Wistar rats: a telemetric study about isoflurane, ketaminexylazine and a combination of medetomidine, midazolam and fentanyl, *BMC Vet. Res.* 10 (2014) 310.
- [39] M. Albrecht, et al., Effects of isoflurane, ketamine-xylazine and a combination of medetomidine, midazolam and fentanyl on physiological variables continuously measured by telemetry in Wistar rats, *BMC Vet. Res.* 10 (2014) 198.

- [40] S. Tzoumas, et al., Eigenspectra optoacoustic tomography achieves quantitative blood oxygenation imaging deep in tissues, *Nat. Commun.* (2016).
- [41] R. Panek, et al., Noninvasive imaging of cycling hypoxia in head and neck cancer using intrinsic susceptibility MRI, *Clin. Cancer Res.* 23 (15) (2017) 4233–4241.




Dr. Márcia Martinho Costa is currently a post-doctoral researcher at the Institute of Cancer Research, studying the potential of therapeutic ultrasound for boosting the immune system response against cancer. She received her Ph.D. degree in biophysics in 2017 from the same Institute, for her work on combined radiotherapy and therapeutic ultrasound in the treatment of hypoxic tumours.



Dr. Anant Shah received his Ph.D. degree in biophysics in 2014 from the Institute Of Cancer Research, for his work on photoacoustic imaging of molecular markers of cancer prognosis and response using gold nanoparticles. He is currently working as a postdoctoral researcher at the Institute of Cancer Research. His research is oriented towards assessing the potential of photoacoustic imaging for cancer treatment planning and treatment response.



Dr. Ian Rivens has over 20 years therapeutic ultrasound research experience ranging from bench to bedside, and including PhD student supervision. This includes, but is not limited to: Phase I and II clinical trials at the Royal Marsden NHS Foundation Trust treating soft tissue tumours, palliating bone pain and treating recurrent gynaecological cancer; design and development of laboratory equipment (including single element and phased array transducers); acoustic cavitation detection and data analysis, and testing of HIFU equipment to investigate cancer treatment techniques including thermal and histotripsy ablation and vascular occlusion.



involved both routine clinical and imaging quality assurance and development of novel photo-acoustic imaging methods.

Dr. Tuathan O'Shea, Ph.D, currently works as a clinical radiation therapy physicist at The Royal Marsden NHS Foundation Trust in central London. He was awarded a Ph.D. in Medical Physics in 2012 for research done in a collaboration between the National University of Ireland Galway and the University of California San Francisco involving development of accurate Monte Carlo simulations of electron linac treatment heads. He has also worked as a post-doctoral researcher in the field of image-guided radiation therapy at The Institute of Cancer Research, London, developing ultrasound-guided radiation therapy techniques and more recently a clinical ultrasound physics role at Royal Marsden NHS Foundation Trust which involved both routine clinical and imaging quality assurance and development of novel photo-acoustic imaging methods.



cellular models of cancer for imaging applications.

Dr. Carol Box is a biologist working in the Centre for Cancer Imaging at the Institute of Cancer Research (ICR), Sutton, London. She obtained a biochemistry degree from the University of Bath and, after a brief spell in industry, obtained a PhD in cancer molecular biology from ICR under the supervision of Dr Christopher Dean. Following this, she undertook postdoctoral work at the Ludwig Institute for Cancer Research (UCL Medical School branch, London) studying phosphoinositide 3-kinase biology with Prof. Bart Vanhaesebroeck. Returning to ICR, she worked with Prof. Sue Eccles on acquired resistance to tyrosine kinase inhibitors in head and neck cancer. Current research interests include therapeutic resistance, tumour hypoxia and 3D cellular models of cancer for imaging applications.



Dr. Efthymia Papaevangelou was born in Drama, Greece. She received the B.Sc. degree in Biology from Aristotle University of Thessaloniki, Greece, the M.Sc. degree in Cancer Therapeutics from Queen Mary's University of London, U.K., and the Ph.D. degree in Cancer Biology and Imaging from St. George's University of London, U.K., in 2006, 2008, and 2013, respectively. From 2013 to 2016, she worked as a Postdoctoral Training Fellow with the Institute of Cancer Research, London, U.K., researching the efficacy and effects of novel tumour therapies on pre-clinical models utilising MRI, MRS and ultrasound imaging modalities. She is currently a Research Associate with King's College London, U.K., investigating the immunological and biological changes caused by novel immunotherapies on prostate cancer models.



Prof. Gail ter Haar is Professor of Therapy Ultrasound at the Institute of Cancer Research, London. She holds degrees in Physics, Medical Physics and Clinical Medicine. Her research addresses applications of therapy ultrasound to cancer, including high intensity focused ultrasound (HIFU), hyperthermia and ultrasound induced immunostimulation. Her team takes ideas from conception, through pre-clinical stages, and into the clinic wherever appropriate. This pathway may include the building of devices for 'proof of concept' patient trials.



Prof. Jeff Bamber is Professor in Physics Applied to Medicine, leader of the Ultrasound and Optical Imaging Team at the Institute of Cancer Research (ICR), London. He has contributed to subjects such as understanding the acoustic characteristics of normal and malignant tissues, ultrasound imaging, elastography and photoacoustic imaging. His current research aims to increase the functional and molecular imaging capability of ultrasound, providing new tools to experimental cancer biology and helping to personalise cancer treatment by bringing the cost-effectiveness, safety, speed and convenience of ultrasonic methods to clinical problems such as assessing tumour aggressiveness and response, and guiding treatment. He is past president of the International Association for Breast Ultrasound and past vice-president of the International Society of Skin Imaging.

past president of the International Association for Breast Ultrasound and past vice-president of the International Society of Skin Imaging.